KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Inventory (2016 - 2025)

Neogenomics' Inventory history spans 16 years, with the latest figure at $28.6 million for Q4 2025.

  • For Q4 2025, Inventory rose 6.8% year-over-year to $28.6 million; the TTM value through Dec 2025 reached $28.6 million, up 6.8%, while the annual FY2025 figure was $28.6 million, 6.8% up from the prior year.
  • Inventory reached $28.6 million in Q4 2025 per NEO's latest filing, roughly flat from $28.5 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $34.2 million in Q2 2025 to a low of $20.3 million in Q1 2024.
  • Average Inventory over 5 years is $24.8 million, with a median of $24.1 million recorded in 2023.
  • Peak YoY movement for Inventory: decreased 20.76% in 2021, then surged 47.2% in 2025.
  • A 5-year view of Inventory shows it stood at $23.4 million in 2021, then increased by 3.77% to $24.3 million in 2022, then fell by 0.5% to $24.2 million in 2023, then increased by 10.73% to $26.7 million in 2024, then rose by 6.8% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Inventory are $28.6 million (Q4 2025), $28.5 million (Q3 2025), and $34.2 million (Q2 2025).